Faeth Therapeutics, Inc. FTH
Faeth Therapeutics, Inc. (Nasdaq: FTH) is an oncology drug developer. Its lead program, PIKTOR (serabelisib + sapanisertib), is in Phase 2 for Second-line advanced endometrial cancer. Its next catalyst on record is PIKTOR - endometrial cancer: Topline data from Phase 2 trial (Study FTH-PIK-201) (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: PIKTOR - endometrial cancer — Topline data from Phase 2 trial (Study FTH-PIK-201) (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PIKTOR (serabelisib + sapanisertib) | Second-line advanced endometrial cancer | small molecule | Phase 2 |
| PIKTOR (serabelisib + sapanisertib) | HR+/HER2- advanced breast cancer | small molecule | Phase 1 |
| Solnerstotug (SNS-101) | Oncology (VISTA checkpoint inhibitor) | antibody | Phase 1 |
Recent results and decisions
- Nov 3, 2026positive FDA granted Fast Track designation to PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer.
FDA granted Fast Track designation to PIKTOR in combination with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR (PAM) pathway alteration.
Filing - Nov 3, 2026n/a FDA granted Fast Track designation to PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer.
FDA granted Fast Track designation to PIKTOR in combination with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR (PAM) pathway alteration.
Filing - May 15, 2026started First patient dosed in April 2026 in Phase 1b/2 PIKTOR trial in HR+/HER2- advanced breast cancer; interim data expected 2027.
In April 2026, the first patient was dosed in the Phase 1b/2 trial evaluating PIKTOR for the treatment of HR+/HER2- advanced breast cancer (Study FTH-PIK-101). Interim data from the trial is expected in 2027.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.